{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:10:15Z","timestamp":1792822215855,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T00:00:00Z","timestamp":1671321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T00:00:00Z","timestamp":1671321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40265-022-01810-3","type":"journal-article","created":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T12:02:21Z","timestamp":1671364941000},"page":"37-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1628-1612","authenticated-orcid":false,"given":"C. D.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Al-Jammali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Herink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,18]]},"reference":[{"key":"1810_CR1","unstructured":"The United States Food and Drug Administration. FDA warns about serious breathing problems with gabapentin and pregabalin; 2019."},{"issue":"5","key":"1810_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMp1704633","volume":"377","author":"CW Goodman","year":"2017","unstructured":"Goodman CW, Brett AS. Gabapentin and pregabalin for pain\u2014is increased prescribing a cause for concern? N Engl J Med. 2017;377(5):411\u20134.","journal-title":"N Engl J Med"},{"issue":"3","key":"1810_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMp1806486","volume":"379","author":"DC Throckmorton","year":"2018","unstructured":"Throckmorton DC, Gottlieb S, Woodcock J. The FDA and the next wave of drug abuse\u2014proactive pharmacovigilance. N Engl J Med. 2018;379(3):205\u20137.","journal-title":"N Engl J Med"},{"issue":"19","key":"1810_CR4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.15585\/mmwr.mm7119a3","volume":"71","author":"CL Mattson","year":"2022","unstructured":"Mattson CL, Chowdhury F, Gilson TP. Notes from the field: trends in gabapentin detection and involvement in drug overdose deaths\u201423 states and the District of Columbia, 2019\u20132020. MMWR Morb Mortal Wkly Rep. 2022;71(19):664\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1810_CR5","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1001\/jama.2022.13659","volume":"328","author":"BM Kuehn","year":"2022","unstructured":"Kuehn BM. Growing role of gabapentin in opioid-related overdoses highlights misuse potential and off-label prescribing practices. JAMA. 2022;328:1283\u20135.","journal-title":"JAMA"},{"issue":"7","key":"1810_CR6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jpain.2022.01.006","volume":"23","author":"LR Gorfinkel","year":"2022","unstructured":"Gorfinkel LR, et al. Trends in prescriptions for non-opioid pain medications among U.S. adults with moderate or severe pain, 2014\u20132018. J Pain. 2022;23(7):1187\u201395.","journal-title":"J Pain"},{"key":"1810_CR7","unstructured":"(CDC), C.f.D.C., Draft CDC Clinical Practice Guideline for Prescribing Opioids\u2014United States, 2022; 2022."},{"key":"1810_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1745-6215-13-136","volume":"13","author":"SS Vedula","year":"2012","unstructured":"Vedula SS, et al. Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation. Trials. 2012;13:136.","journal-title":"Trials"},{"issue":"12","key":"1810_CR9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMoa1614292","volume":"376","author":"S Mathieson","year":"2017","unstructured":"Mathieson S, et al. Trial of pregabalin for acute and chronic sciatica. N Engl J Med. 2017;376(12):1111\u201320.","journal-title":"N Engl J Med"},{"key":"1810_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5992","volume":"347","author":"EH Turner","year":"2013","unstructured":"Turner EH. How to access and process FDA drug approval packages for use in research. BMJ. 2013;347: f5992.","journal-title":"BMJ"},{"issue":"6","key":"1810_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/papr.12014","volume":"13","author":"R Rauck","year":"2013","unstructured":"Rauck R, et al. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Pract. 2013;13(6):485\u201396.","journal-title":"Pain Pract"},{"issue":"12","key":"1810_CR12","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1179\/1743132814Y.0000000404","volume":"36","author":"H Dolgun","year":"2014","unstructured":"Dolgun H, et al. Gabapentin versus pregabalin in relieving early post-surgical neuropathic pain in patients after lumbar disc herniation surgery: a prospective clinical trial. Neurol Res. 2014;36(12):1080\u20135.","journal-title":"Neurol Res"},{"issue":"12","key":"1810_CR13","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1212\/WNL.0000000000003118","volume":"87","author":"J French","year":"2016","unstructured":"French J, et al. Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes. Neurology. 2016;87(12):1242\u20139.","journal-title":"Neurology"},{"issue":"4","key":"1810_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2217\/pmt-2018-0005","volume":"8","author":"P Schmidt","year":"2018","unstructured":"Schmidt P, Rao S. Effects of gabapentin, pregabalin and gastroretentive gabapentin on simulated driving, daytime sedation and cognition. Pain Manag. 2018;8(4):297\u2013306.","journal-title":"Pain Manag"},{"issue":"1","key":"1810_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaneurol.2018.3077","volume":"76","author":"K Robertson","year":"2018","unstructured":"Robertson K, et al. Effect of gabapentin vs pregabalin on pain intensity in adults with chronic sciatica (PAGPROS). JAMA Neurol. 2018;76(1):28\u201334.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1810_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/1049909111412539","volume":"29","author":"S Mishra","year":"2012","unstructured":"Mishra S, et al. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care. 2012;29(3):177\u201382.","journal-title":"Am J Hosp Palliat Care"},{"key":"1810_CR17","doi-asserted-by":"publisher","first-page":"4078695","DOI":"10.1155\/2016\/4078695","volume":"2016","author":"A Mimenza Alvarado","year":"2016","unstructured":"Mimenza Alvarado A, Aguilar Navarro S. Clinical trial assessing the efficacy of gabapentin plus B complex (B1\/B12) versus pregabalin for treating painful diabetic neuropathy. J Diabetes Res. 2016;2016:4078695.","journal-title":"J Diabetes Res"},{"issue":"6","key":"1810_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40261-013-0080-2","volume":"33","author":"H Atalay","year":"2013","unstructured":"Atalay H, et al. Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clin Drug Investig. 2013;33(6):401\u20138.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"1810_CR19","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s11255-012-0193-1","volume":"45","author":"Z Biyik","year":"2013","unstructured":"Biyik Z, et al. Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. Int Urol Nephrol. 2013;45(3):831\u20137.","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"1810_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2174\/1574887116666210201110507","volume":"16","author":"O Gammoh","year":"2021","unstructured":"Gammoh O, et al. The clinical difference between gabapentin and pregabalin: data from a pilot comparative trial. Rev Recent Clin Trials. 2021;16(3):279\u201387.","journal-title":"Rev Recent Clin Trials"},{"issue":"8","key":"1810_CR21","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/j.1440-1797.2012.01655.x","volume":"17","author":"Y Solak","year":"2012","unstructured":"Solak Y, et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology (Carlton). 2012;17(8):710\u20137.","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"1810_CR22","doi-asserted-by":"publisher","first-page":"E363","DOI":"10.1097\/BRS.0000000000000185","volume":"39","author":"G Khurana","year":"2014","unstructured":"Khurana G, et al. Postoperative pain and long-term functional outcome after administration of gabapentin and pregabalin in patients undergoing spinal surgery. Spine (Phila Pa 1976). 2014;39(6):E363\u20138.","journal-title":"Spine (Phila Pa 1976)"},{"key":"1810_CR23","doi-asserted-by":"publisher","first-page":"9834059","DOI":"10.1155\/2018\/9834059","volume":"2018","author":"MS Nakhli","year":"2018","unstructured":"Nakhli MS, et al. Effects of gabapentinoids premedication on shoulder pain and rehabilitation quality after laparoscopic cholecystectomy: pregabalin versus gabapentin. Pain Res Manag. 2018;2018:9834059.","journal-title":"Pain Res Manag"},{"issue":"11","key":"1810_CR24","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1097\/AJP.0000000000000060","volume":"30","author":"MS Bekawi","year":"2014","unstructured":"Bekawi MS, et al. Clinical study evaluating pregabalin efficacy and tolerability for pain management in patients undergoing laparoscopic cholecystectomy. Clin J Pain. 2014;30(11):944\u201352.","journal-title":"Clin J Pain"},{"issue":"12","key":"1810_CR25","first-page":"883","volume":"52","author":"E Ozgencil","year":"2011","unstructured":"Ozgencil E, et al. Perioperative administration of gabapentin 1,200 mg day-1 and pregabalin 300 mg day-1 for pain following lumbar laminectomy and discectomy: a randomised, double-blinded, placebo-controlled study. Singapore Med J. 2011;52(12):883\u20139.","journal-title":"Singapore Med J"},{"issue":"Suppl 7","key":"1810_CR26","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.5301\/ejo.5000143","volume":"22","author":"M Pakravan","year":"2012","unstructured":"Pakravan M, et al. Pregabalin and gabapentin for post-photorefractive keratectomy pain: a randomized controlled trial. Eur J Ophthalmol. 2012;22(Suppl 7):S106\u201313.","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"1810_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/0022-3859.128801","volume":"60","author":"CK Pandey","year":"2014","unstructured":"Pandey CK, et al. Comparative evaluation of prophylactic use of pregabalin, gabapentin and diclofenac sodium for prevention of succinylcholine-induced myalgia: a randomized, double-blinded study. J Postgrad Med. 2014;60(1):16\u201320.","journal-title":"J Postgrad Med"},{"key":"1810_CR28","unstructured":"USFDA, Review and evaluation of clinical data for gabapentin, H.a.H. Services, Editor; 2002, USFDA: Online."},{"key":"1810_CR29","unstructured":"USFDA. Statistical review and evaluation of neurontin, H.a.H. Services, Editor; 2002, Center for Drug Evaluation and Research: Online."},{"issue":"21","key":"1810_CR30","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","volume":"280","author":"M Backonja","year":"1998","unstructured":"Backonja M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280(21):1831\u20136.","journal-title":"JAMA"},{"issue":"3","key":"1810_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0304-3959(02)00255-5","volume":"99","author":"MG Serpell","year":"2002","unstructured":"Serpell MG, Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99(3):557\u201366.","journal-title":"Pain"},{"issue":"1","key":"1810_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0149-2918(03)90011-7","volume":"25","author":"M Backonja","year":"2003","unstructured":"Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther. 2003;25(1):81\u2013104.","journal-title":"Clin Ther"},{"issue":"2","key":"1810_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0304-3959(01)00407-9","volume":"94","author":"ASC Rice","year":"2001","unstructured":"Rice ASC, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94(2):215\u201324.","journal-title":"Pain"},{"issue":"21","key":"1810_CR34","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1001\/jama.280.21.1837","volume":"280","author":"M Rowbotham","year":"1998","unstructured":"Rowbotham M, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280(21):1837\u201342.","journal-title":"JAMA"},{"key":"1810_CR35","unstructured":"USFDA. Lyrica Prescribing Information; 2020."},{"key":"1810_CR36","unstructured":"USFDA. USFDA review of pregabalin for post-herpetic neuralgia; 2004."},{"key":"1810_CR37","unstructured":"USFDA. USFDA review of pregabalin for diabetic peripheral neuropathy; 2004."},{"issue":"4","key":"1810_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","volume":"6","author":"RW Richter","year":"2005","unstructured":"Richter RW, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6(4):253\u201360.","journal-title":"J Pain"},{"issue":"11","key":"1810_CR39","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1212\/01.WNL.0000145767.36287.A1","volume":"63","author":"H Lesser","year":"2004","unstructured":"Lesser H, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63(11):2104\u201310.","journal-title":"Neurology"},{"issue":"3","key":"1810_CR40","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","volume":"110","author":"J Rosenstock","year":"2004","unstructured":"Rosenstock J, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110(3):628\u201338.","journal-title":"Pain"},{"issue":"2","key":"1810_CR41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejpain.2007.05.003","volume":"12","author":"T Tolle","year":"2008","unstructured":"Tolle T, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12(2):203\u201313.","journal-title":"Eur J Pain"},{"issue":"1\u20132","key":"1810_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pain.2004.01.001","volume":"109","author":"R Sabatowski","year":"2004","unstructured":"Sabatowski R, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004;109(1\u20132):26\u201335.","journal-title":"Pain"},{"issue":"8","key":"1810_CR43","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1212\/01.WNL.0000055433.55136.55","volume":"60","author":"RH Dworkin","year":"2003","unstructured":"Dworkin RH, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60(8):1274\u201383.","journal-title":"Neurology"},{"issue":"2","key":"1810_CR44","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1185\/030079906X80404","volume":"22","author":"R van Seventer","year":"2006","unstructured":"van Seventer R, et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin. 2006;22(2):375\u201384.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1810_CR45","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1212\/01.wnl.0000244422.45278.ff","volume":"67","author":"PJ Siddall","year":"2006","unstructured":"Siddall PJ, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology. 2006;67(10):1792\u2013800.","journal-title":"Neurology"},{"issue":"6","key":"1810_CR46","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1212\/WNL.0b013e318281546b","volume":"80","author":"DD Cardenas","year":"2013","unstructured":"Cardenas DD, et al. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology. 2013;80(6):533\u20139.","journal-title":"Neurology"},{"key":"1810_CR47","unstructured":"USFDA. FDA Review of pregabalin for fibromyalgia; 2007."},{"issue":"4","key":"1810_CR48","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/art.20983","volume":"52","author":"LJ Crofford","year":"2005","unstructured":"Crofford LJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(4):1264\u201373.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1810_CR49","first-page":"502","volume":"35","author":"PJ Mease","year":"2008","unstructured":"Mease PJ, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35(3):502\u201314.","journal-title":"J Rheumatol"},{"issue":"9","key":"1810_CR50","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","volume":"9","author":"LM Arnold","year":"2008","unstructured":"Arnold LM, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9(9):792\u2013805.","journal-title":"J Pain"},{"issue":"3","key":"1810_CR51","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.pain.2008.02.027","volume":"136","author":"LJ Crofford","year":"2008","unstructured":"Crofford LJ, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136(3):419\u201331.","journal-title":"Pain"},{"issue":"11","key":"1810_CR52","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/14737175.2016.1202764","volume":"16","author":"EP Calandre","year":"2016","unstructured":"Calandre EP, Rico-Villademoros F, Slim M. Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert Rev Neurother. 2016;16(11):1263\u201377.","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"1810_CR53","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","volume":"49","author":"HN Bockbrader","year":"2010","unstructured":"Bockbrader HN, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661\u20139.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1810_CR54","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1212\/WNL.0b013e3181d25b34","volume":"74","author":"M Salinsky","year":"2010","unstructured":"Salinsky M, Storzbach D, Munoz S. Cognitive effects of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial. Neurology. 2010;74(9):755\u201361.","journal-title":"Neurology"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01810-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01810-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01810-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T05:12:15Z","timestamp":1673413935000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01810-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,18]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1810"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01810-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,18]]},"assertion":[{"value":"13 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was provided for this project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are available on request from the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors conducted an independent review of the FDA review packets and of Pubmed for relevant clinical trials. CDW: conceptualization, supervision, writing, review, and editing. ZAJ and MCH: writing, review, and editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}